Zobrazeno 91 - 100
of 159
pro vyhledávání: '"Diwakar Davar"'
Autor:
Nathan Bahary, Diwakar Davar
Publikováno v:
Targeted Oncology. 13:125-140
Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) catalyze the first rate-limiting step in the oxidative metabolism of compounds containing indole rings, including the transformation of the essential amino acid L-tryptophan to N-
Autor:
Hassane M. Zarour, Richelle DeBlasio, Marc Schwartz, Stephanie Prescott, Ivan Vujkovic-Cvijin, Amy Rose, Marie Vétizou, Scarlett J. Ernst, Jonathan H. Badger, Howard M. Dubner, Hong Wang, Yasmine Belkaid, John M. Kirkwood, Ascharya K. Balaji, Amiran Dzutsev, Diwakar Davar, Yana G. Najjar, Quanquan Ding, Raquel Galvão Figueredo Costa, Joe-Marc Chauvin, Shuowen Zhang, Carmine Menna, Amir A. Borhani, Giorgio Trinchieri, John A. McCulloch, Bochra Zidi, Richard R. Rodrigues, Ornella Pagliano, Miriam R. Fernandes, Andrey Morgun, Robert M. Morrison, Alicia M. Cole
Publikováno v:
Cancer Research. 81:LB062-LB062
Background: Monoclonal antibodies (mAb) targeting the programmed cell death protein 1 (PD-1) receptor provide durable long-term benefit in a subset of patients (pts) with advanced melanoma with response rates of 35-42% and 4-year progression-free sur
Autor:
Wael A. Harb, Jing Yang, Diwakar Davar, Justin C. Moser, Gary Means, Hany Zayed, Almudena Tercero, Kristi Manjarrez, Stanford L. Peng, Graciela Noemi Perez, Jan Hillson, Christine Dela Cruz, Michael Millward, Mark Voskoboynik, Nehal Lakhani
Publikováno v:
Cancer Research. 81:CT213-CT213
BACKGROUND: Checkpoint inhibitors (CPI) targeting the PD-1 and CTLA-4 pathways have demonstrated significant clinical benefit in multiple tumors, but the majority of patients exhibit or develop resistance, at least in part due to insufficient activat
Autor:
Inderjit Mehmi, Katie M. Campbell, Aaron Morris, Dmitri Bobilev, Geoffrey T. Gibney, Adil Daud, Riyue Bao, Theresa Medina, Jason J. Luke, Takami Sato, Yousef Zakharia, Kim Margolin, Arthur M. Krieg, George J. Weiner, Diwakar Davar, Elizabeth I. Buchbinder, James E. Wooldridge, Jiaxin Niu, Anthony J. Olszanski, Mohammed M. Milhem, Montaser Shaheen, John M. Kirkwood, Antoni Ribas
Publikováno v:
Cancer Research. 81:CT032-CT032
Background In the treatment-naive setting, PD-1 blockade is associated with greater response in T cell-inflamed vs non-T cell-inflamed tumors. CMP-001 is a CpG-A oligonucleotide TLR9 agonist in a virus-like particle that is hypothesized to activate t
Autor:
Jing Yang, Mark Voskoboynik, Justin C. Moser, Diwakar Davar, Michael Millward, Christine Dela Cruz, Kristi Manjarrez, Stanford L. Peng, Wael A. Harb, Graciela Noemi Perez, Jan Hillson, Gary Means, Nehal Lakhani, Almudena Tercero, Hany Zayed
Publikováno v:
Journal of Clinical Oncology. 39:2547-2547
2547 Background: Strong preclinical rationale has emerged for combining checkpoint inhibition (CPI) with T cell costimulatory agonists, particularly CD28, a critical T cell costimulatory molecule recently recognized as a key target of checkpoint inhi
Autor:
Andres Forero-Torres, Rachel E. Sanborn, Elena Garralda, Francine M. Foss, Anna Minchom, Vincent Ribrag, Diwakar Davar, Giuseppe Curigliano, Stephen M. Ansell, Amitkumar Mehta, Jasmine Zain
Publikováno v:
Journal of Clinical Oncology. 39:TPS2657-TPS2657
TPS2657 Background: T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory immune checkpoint receptor expressed on subsets of T cells and NK cells. SEA-TGT is an effector-function enhanced human mAb that targets TIGIT with pico-molar
Autor:
Diwakar Davar, Yana G. Najjar, Hassane M. Zarour, Xi Yang, Hong Wang, John M. Kirkwood, Jason J. Luke, Dylan Fortman, Saba Shaikh
Publikováno v:
Journal of Clinical Oncology. 39:e21579-e21579
e21579 Background: The COVID-19 pandemic has impacted cancer care beyond the direct implications of viral infection. Delays in presentation and diagnosis may lead to more advanced disease and worse patient outcomes. We evaluated the impact of the pan
A phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with advanced melanoma
Autor:
Saba Shaikh, Yan Zang, Diwakar Davar, Hassane M. Zarour, Hong Wang, Yana G. Najjar, John M. Kirkwood, Janel Hanmer, Yan Lin
Publikováno v:
Journal of Clinical Oncology. 39:e21506-e21506
e21506 Background: Management of patients (pts) with advanced melanoma includes anti-PD1 with or without anti-CTLA4, and for pts with a BRAF mutation, the additional option of targeted therapy. Preclinical and translational evidence suggest BRAF/MEK
Autor:
S. M. Ansell, Amitkumar Mehta, Giuseppe Curigliano, Francine M. Foss, Rachel E. Sanborn, Anna Minchom, Vincent Ribrag, Phillip M. Garfin, Diwakar Davar, Elena Garralda
Publikováno v:
Annals of Oncology. 31:S729-S730
Autor:
John M. Kirkwood, Stephanie R. Jackson Cullison, Laura K. Ferris, Neil A. Houston, Matthew P. Holtzman, Galen E. Switzer, Rebecca Liu, Nalyn Siripong, Diwakar Davar, Sophia Zhang, Keely Marshall, Yana G. Najjar
Publikováno v:
Journal of the American Academy of Dermatology. 83(2)